These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31331770)

  • 21. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever.
    Abreu-Mota T; Hagen KR; Cooper K; Jahrling PB; Tan G; Wirblich C; Johnson RF; Schnell MJ
    Nat Commun; 2018 Oct; 9(1):4223. PubMed ID: 30310067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a new vaccine for the prevention of Lassa fever.
    Geisbert TW; Jones S; Fritz EA; Shurtleff AC; Geisbert JB; Liebscher R; Grolla A; Ströher U; Fernando L; Daddario KM; Guttieri MC; Mothé BR; Larsen T; Hensley LE; Jahrling PB; Feldmann H
    PLoS Med; 2005 Jun; 2(6):e183. PubMed ID: 15971954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein.
    Djavani M; Yin C; Xia L; Lukashevich IS; Pauza CD; Salvato MS
    Vaccine; 2000 Feb; 18(15):1543-54. PubMed ID: 10618553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.
    Dowall SD; Buttigieg KR; Findlay-Wilson SJ; Rayner E; Pearson G; Miloszewska A; Graham VA; Carroll MW; Hewson R
    Hum Vaccin Immunother; 2016; 12(2):519-27. PubMed ID: 26309231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus.
    Morrison HG; Goldsmith CS; Regnery HL; Auperin DD
    Virus Res; 1991 Mar; 18(2-3):231-41. PubMed ID: 2042398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine strategies against Babesia bovis based on prime-boost immunizations in mice with modified vaccinia Ankara vector and recombinant proteins.
    Jaramillo Ortiz JM; Del Médico Zajac MP; Zanetti FA; Molinari MP; Gravisaco MJ; Calamante G; Wilkowsky SE
    Vaccine; 2014 Aug; 32(36):4625-32. PubMed ID: 24968152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara.
    Staib C; Kisling S; Erfle V; Sutter G
    J Gen Virol; 2005 Jul; 86(Pt 7):1997-2006. PubMed ID: 15958679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial.
    Milligan ID; Gibani MM; Sewell R; Clutterbuck EA; Campbell D; Plested E; Nuthall E; Voysey M; Silva-Reyes L; McElrath MJ; De Rosa SC; Frahm N; Cohen KW; Shukarev G; Orzabal N; van Duijnhoven W; Truyers C; Bachmayer N; Splinter D; Samy N; Pau MG; Schuitemaker H; Luhn K; Callendret B; Van Hoof J; Douoguih M; Ewer K; Angus B; Pollard AJ; Snape MD
    JAMA; 2016 Apr; 315(15):1610-23. PubMed ID: 27092831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
    Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease.
    Rall I; Amann R; Malberg S; Herden C; Rubbenstroth D
    Viruses; 2019 Dec; 11(12):. PubMed ID: 31817690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Scholte FEM; Goldsmith CS; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2019 Sep; 220(8):1281-1289. PubMed ID: 31152662
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.
    ter Meulen J; Badusche M; Kuhnt K; Doetze A; Satoguina J; Marti T; Loeliger C; Koulemou K; Koivogui L; Schmitz H; Fleischer B; Hoerauf A
    J Virol; 2000 Mar; 74(5):2186-92. PubMed ID: 10666248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.
    Salvato MS; Domi A; Guzmán-Cardozo C; Medina-Moreno S; Zapata JC; Hsu H; McCurley N; Basu R; Hauser M; Hellerstein M; Guirakhoo F
    Pathogens; 2019 Aug; 8(3):. PubMed ID: 31466243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen.
    Hanke T; Samuel RV; Blanchard TJ; Neumann VC; Allen TM; Boyson JE; Sharpe SA; Cook N; Smith GL; Watkins DI; Cranage MP; McMichael AJ
    J Virol; 1999 Sep; 73(9):7524-32. PubMed ID: 10438842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
    He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
    Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.
    de Waal L; Wyatt LS; Yüksel S; van Amerongen G; Moss B; Niesters HG; Osterhaus AD; de Swart RL
    Vaccine; 2004 Feb; 22(8):923-6. PubMed ID: 15161069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.